1. Japan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Cosmo Bio Co., Ltd.

Cosmo Bio Co., Ltd.

TTSE:3386
1,230.00
JPY
-4.00
(-0.32%)
7.00BMarket Cap
Nov 06Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,189.27
1,220.48
1,241.06
1,252.87
1,192.31
1,224.87
1,280.36
1,365.07
1,589.14
1,645.56
1,602.48
1,725.8
1,893.02
- -
Basic EPS, GAAP
52.8
33.91
38.8
42.85
39.98
43.86
39.98
113.7
126.88
89.06
75.83
45.05
59.26
- -
Free Cash Flow per Basic Share
9.28
38.29
-7.76
56.68
-75.07
129.55
63.77
124.5
87.28
31.01
109.12
-6.02
55.21
- -
Dividend per Share
19.91
19.91
17.88
15.86
17.88
13.83
13.83
15.86
38.39
39.96
33.8
30.09
61.19
- -
Book Value per Share
1,064.61
1,020.58
1,003.88
1,034.92
1,076.25
1,109.82
1,154.01
1,241.07
1,344.13
1,385.09
1,447.04
1,564.69
1,651.94
1,712.38
Tangible Book Value per Share
1,046.9
1,004.05
966.26
988.7
1,034.24
1,067.31
1,120.45
1,213.23
1,312.71
1,355.68
1,420.48
1,536.42
1,622.5
1,683.42
Basic Weighted Avg Shares
6
6
6
6
6
6
6
6
6
6
6
6
6
6
Sales/Revenue/Turnover
7,050
7,235
7,357
7,427
7,068
7,261
7,590
8,092
9,231
9,553
9,340
10,037
10,766
- -
Operating Margin (%)
3.86
2.25
2.73
6.93
2.73
4.53
5.34
9.31
11.36
8.54
5.57
3.18
3.19
- -
Depreciation Expense
96
84
79
85
156
178
207
175
166
141
148
136
167
- -
Net Income, GAAP
313
201
230
254
237
260
237
674
737
517
442
262
337
- -
Effective Tax Rate (%)
30.38
39.7
38.82
39.47
37.25
31.02
36.6
30.46
30.03
30.13
29.25
26.83
33.73
- -
Profit Margin (%)
4.44
2.78
3.13
3.42
3.35
3.58
3.12
8.33
7.98
5.41
4.73
2.61
3.13
- -
Working Capital
4,709
4,104
4,249
4,579
4,344
4,703
4,940
5,530
6,217
6,098
5,979
6,063
6,019
6,849
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
6,797
6,532
6,378
6,581
6,837
7,051
7,319
7,860
8,317
8,617
9,025
9,553
9,955
10,348
Return on Invested Capital (%)
2.96
1.44
1.86
4.71
1.78
3.22
3.52
6.72
8.83
6.62
4.11
2.48
2.31
- -
Return on Capital (%)
4.97
3.02
3.26
3.57
3.34
3.49
3.18
8.5
8.71
5.68
4.78
2.74
3.48
- -
Return on Common Equity (%)
5.42
3.25
3.83
4.2
3.79
4.01
3.53
9.49
9.73
6.53
5.36
3.01
3.68
- -

Capital Structure

JPY

•

in mil. unless spec.
Mar'24
Jun'24
Jun'26
ST Debt
20
20
20
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
5,952
6,117
6,997

Working Capital

JPY

•

in mil. unless spec.
Mar'24
Jun'24
Jun'26
Total Current Assets
7,360
7,179
7,930
Cash, Cash Equivalents & STI
2,813
3,224
4,068
Accounts Receivable, Net
3,399
2,689
2,601
Inventories
990
1,051
1,006
Total Current Liabilities
1,236
976
1,081
Payables & Accruals
- -
- -
- -
ST Debt
20
20
20
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.56%
4.84%
4.21%
Free Cash Flow
-223.61%
-189.02%
-997.14%
Net Income, GAAP
14.19%
-9.42%
28.63%
Sales/Revenue/Turnover
4%
6.01%
7.26%
Total Cash Common Dividend
- -
42.77%
98.86%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,943
2,186
- -
- -
10,037
2025
- -
- -
- -
- -
10,766
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39.42
4.78
- -
- -
45.05
2025
- -
- -
- -
- -
59.26
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
30.09
2025
- -
- -
- -
- -
61.19
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Norihiko Shibayama
Full Time Employees
182
Sector
Distribution services
Industry
Medical distributors
Address
Toyo-Ekimae Building Tokyo TY Japan 135-0016
IPO Date
Sep 27, 2005
Website
cosmobio.co.jp
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Cosmo Bio Company, Limited is a biotechnology company primarily engaged in the manufacture and sale of biochemical products and reagents used in life science research and clinical diagnostics. Its main product portfolio includes laboratory reagents; peptide synthesis reagents; antibodies; cell culture media; molecular biology kits; biochemicals; custom synthesis services; and diagnostic testing kits. The company serves research institutions, pharmaceutical companies, and clinical laboratories, primarily within Japan but also internationally. Founded in 1978, Cosmo Bio Company is headquartered in Tokyo, Japan. Recent major developments include strategic expansions in its product offerings and enhancements in its custom synthesis services to cater to the growing demand for specialized biochemicals and reagents. The company has focused on strengthening its technological capabilities and broadening its partnerships to support advancements in life sciences and medical research. These operational enhancements reinforce its position in the biotechnology and life sciences industry, emphasizing innovation and comprehensive product support. Cosmo Bio operates primarily in the biotechnology industry, serving segments that include academic research, pharmaceuticals, and clinical diagnostics. The company's businesses target institutional researchers and healthcare providers requiring high-quality biochemical tools and reagents. It maintains a strong presence domestically in Japan, with increasing outreach to global markets through partnerships and distribution networks. The company continues to leverage its long-standing expertise in biochemical product development, manufacturing, and supply chain management to meet evolving customer needs in life sciences. It has not reported any recent name changes or reorganization but is actively expanding its technological and service offerings to reinforce market competitiveness. Overall, Cosmo Bio Company, Limited is a well-established biotechnology firm headquartered in Tokyo, providing a detailed and diversified product range of biochemical reagents, diagnostic kits, and custom synthesis services, with recent strategic developments aimed at expanding service capabilities and innovation in the life science sector.